Editorial: The complex relationship between cholesterol and brain hemorrhage

Circulation

Volumn 119, Issue 16, 2009, Pages 2131-2133

  Goldstein, Larry B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Editorials; Hemorrhage; Lipids; Stroke

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

BRAIN HEMORRHAGE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DISEASE ASSOCIATION; EDITORIAL; GROUPS BY AGE; JAPANESE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; HUMAN; META ANALYSIS; METABOLISM; NOTE;

CHOLESTEROL, LDL; HUMANS; INTRACRANIAL HEMORRHAGES; META-ANALYSIS AS TOPIC; RISK FACTORS;

EID: 66549118845     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.856385     Document Type: Editorial

References (15)

1. Noda H, Iso H, Irie F, Sairenchi T, Ohtaka E, Doi M, Izumi Y, Ohta H. Low-density lipoprotein cholesterol concentrations and death due to intrapa- renchymal hemorrhage: The Ibaraki Prefectural Health study. Circulation. 2009;119:2136-2145.
2. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007; 370:1829-1839.
3. Iso H, Jacobs DRJ, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N EnglJ Med. 1989;320: 904-910.
4. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, MacMahon S, Woodward M. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol. 2003;32:563-572.
5. Sturgeon JD, Folsom AR, Longstreth WT Jr, Shahar E, Rosamond WD, Cushman M. Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke. 2007;38:2718-2725.
6. Lee SH, Bae HJ, Yoon B-W, Kim H, Kim DE, Roh JK. Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic resonance imaging: analysis of risk factors for multifocal signal loss lesions. Stroke. 2002;33:2845-2849.
7. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366: 1267-1278.
8. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med. 2008; 121:24 -33.
9. Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushiro T, Teramoto T, Uchiyama S, Nakamura H. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA Study). Circulation. 2008;117:494-502.
10. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46:1411-1416.
11. Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2006;48: 1793-1799.
12. Heart Protection Study Collaborative Group. Effects of cholesterol- lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-767.
13. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549 -559.
14. Goldstein LB, Amarenco P, Szarek M, Callahan A, Hennerici M, Sillesen H, Zivin J, Welch KMA. Secondary analysis of hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Neurology. 2008;70:2364-2370.
15. Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A, Hennerici M, Simunovic L, Zivin JA, Welch KMA. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2007;38:3198-3204.